Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

SAN FRAN­CIS­CO — Ul­tragenyx, the com­mer­cial-stage Cal­i­for­nia biotech work­ing on ul­tra-rare dis­eases, is fin­ish­ing up a $50 mil­lion Se­ries A fundraise for its Alzheimer’s gene ther­a­py spin­out, named Am­logenyx, CEO Emil Kakkis told End­points News. 

“We have a lead in­vestor signed on, and we have sev­er­al in­vestors who are on board. We’re still try­ing to fill out a $50 mil­lion syn­di­cate,” Kakkis said on the side­lines of this year’s JP Mor­gan Health­care Con­fer­ence on Mon­day. “We have most of it, or a good part of it, so we’re try­ing to get the last two, three peo­ple to fin­ish it.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER